Foundation Medicine Prices IPO, Expects to Raise $77.4M | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine expects to price its initial public offering at between $14 and $16 per share, the company said in a recently amended Form S-1.

The Cambridge, Mass.-based cancer genomics firm added that it plans to offer 5 million shares, and that based on the midpoint price of $15 per share, it expects net proceeds of $66.9 million from its IPO.

Foundation plans to trade on the Nasdaq under ticker symbol "FMI."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."